Halozyme Therapeutics, Inc. · NASDAQ:HALO
Halozyme Therapeutics — J.P. Morgan Healthcare Conference 2012
21 slides from Halozyme Therapeutics's conference presentation, Jan 9, 2012
Slide 1: Thinking Outside the Cell
Halozyme Therapeutics, Inc. Thinking Outside the Cell(tm) J.P. Morgan Healthcare Conference January 11, 2012 Gregory I. Frost, Ph.D. President and Chief Executive Officer
Slide 2: Safe harbor
Safe harbor All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements and all references to financial estimates are based up
Slide 3: Taking research "outside the cell" towards improved patient care
Taking research "outside the cell" towards improved patient care A family of unique molecular structures that provide support for cells in the body Medium for intercellular communication Enables intravenous (IV) medications to be delivered subcutaneously (SC) Enhances performance of currently-availa
Slide 4: rHuPH20 degrades hyaluronan in the ECM, clearing a pathway for therapeutic agents
rHuPH20 degrades hyaluronan (HA) in the ECM, clearing a pathway for therapeutic agents Inactivation of rHuPH20 and the return of the ECM rapidly restores tissue integrity. ....allowing exposure to capillaries and lymphatics. ....rHuPH20, our core technology, decreases local resistance to the injecti
Slide 5: Halozyme's pipeline is positioned to capture value across a broad range of therapeutic areas
Halozyme's pipeline is positioned to capture value across a broad range of therapeutic areas and geographies
Slide 6: Our four strategic drivers focus on the highest-value opportunities
Our four strategic drivers focus on the highest-value opportunities for the business Secure revenue streams from existing channels Build new partnerships Manage business toward positive cash flow Advance proprietary programs
Slide 7: Our partnered programs may increase convenience and safety while reducing cost of care
Our partnered programs may increase the convenience, and safety of therapies while reducing the cost of care Alpha 1-antitrypsin (pre-clinical)
Slide 8: With late-stage shots-on-goal, the Roche partnership could bring significant near-term value
With 2 late-stage "shots-on-goal," the Roche partnership could bring significant near-term value Registration trial met primary endpoints SC administration of fixed dose co-formulation reduced dosing time to ?5 minutes, versus 30 minutes with IV Preference trial comparing IV to SC auto- injector dev
Slide 9: HyQ may allow convenient, monthly SC dosing at a single injection site
HyQ (GAMMAGARD(r) + rHuPH20) may allow convenient, monthly SC dosing at a single injection site Economics $1B+ product franchise for Baxter ~ $6B worldwide market Halozyme to receive milestone and royalty payments Phase 3 Clinical Trial Primary endpoints were met Achieved bioavailability comparable
Slide 10: Our proprietary programs leverage our ability to enhance drug efficacy
Our proprietary programs leverage our ability to enhance drug efficacy and unveil new opportunities Hylenex Low dose rHuPH20 approved for dispersion and absorption of drugs and fluids Ultrafast Insulin Analog insulin formulated with rHuPH20 for treatment of diabetes PEGPH20 PEGylated rHuPH20 enzyme
Slide 11: Hylenex: Now available for patients
Hylenex(r): Now available for patients Hospitals and emergency departments for drug extravasation and fluid administration in small children FDA approved Wholly owned by Halozyme Initial Commercial Focus Recombinant human enzyme indicated for the dispersion and absorption of other injected drugs and
Slide 12: Analog insulin + rHuPH20 faster-in and faster-out profile may lead to superior glycemic control
Analog insulin + rHuPH20's faster-in and faster-out profile may lead to superior glycemic control
Slide 13: Analog insulin + rHuPH20 faster-in and faster-out profile may lead to superior glycemic control
Analog insulin + rHuPH20's faster-in and faster-out profile may lead to superior glycemic control AACE Ideal Range
Slide 14: We aim to develop best-in-class rapid-acting insulin therapies
We aim to develop best-in-class rapid-acting insulin therapies that surpass current standards of care Completed numerous clinical studies with multiple daily injection (MDI) therapies and continuous subcutaneous insulin infusion (CSII) All studies demonstrated a faster-in, faster-out profile which l
Slide 15: PEGPH20 depletes hyaluronan, potentially a novel mechanism for cancer treatment
PEGPH20 depletes hyaluronan (HA), potentially representing a novel mechanism for cancer treatment HA-rich halos are found on many types of aggressive cancers Pericellular HA Matrix Constricted Blood Flow Normalized Blood Flow Before PEGPH20 Dosing After PEGPH20 Dosing PEGPH20 depletes HA and normali
Slide 16: With PEGPH20, our goal is to turn challenging cancers into a manageable disease
With PEGPH20, our goal is to turn challenging cancers into a manageable disease Accumulation of HA is found in 20-30% of the most prevalent solid tumors, however, 87% of pancreatic ductal adenocarcinomas accumulate high HA Randomized phase 1b/2 study of gemcitabine in combination with PEGPH20 in pat
Slide 17: Disfiguring scars and aesthetic conditions have few viable treatment options
Disfiguring scars and aesthetic conditions, such as cellulite, have few viable treatment options HTI-501 has been shown preclinically to locally break down the collagen fibrils that may cause cellulite Collagen degradation is controlled in the body post-injection through a pH-dependent shut-off mech
Slide 18: Our four strategic drivers focus on the highest-value opportunities
Our four strategic drivers focus on the highest-value opportunities for the business Secure revenue streams from existing channels Build new partnerships Manage business toward positive cash flow Advance proprietary programs Hylenex sales Regular stream of milestone and royalty payments Actively pur
Slide 19: Anticipated launches of proprietary and partnered programs will drive additional revenue
The anticipated launch of proprietary products and partnered programs will drive additional revenue We ended 2011 with a net cash burn of ?$30M and ?$53M in cash Anticipated product revenue and royalty streams may enable us to achieve break-even cash flow in 2013 2011 2012 2013 New Deals Hylenex New
Slide 20: 2011 was a year of strong execution, with all major milestones achieved
2011 was a year of strong execution, with all major milestones achieved Q1 Q2 Q3 Q4 Roche dosed first patient in P3 MabThera study Presented P1 data from analog insulin pump study with rHuPH20 at AACE Signed deal worth up to $63M with Intrexon to develop SC A1T Baxter filed HyQ BLA Signed deal worth
Slide 21: Milestones for proprietary and partnered programs
Milestones (for proprietary and partnered programs) Present full data set from phase 3 SC Herceptin trial Present HTI-501 clinical proof-of-concept data File SC Herceptin marketing application in EU File SC MabThera marketing application in EU Launch HyQ (pending regulatory approval) Initiate phase
Halozyme Therapeutics — J.P. Morgan Healthcare Conference 2012 on 6ix